• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by GlycoMimetics, Inc.

    < Previous 1 2 Next >
    GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics Announces Its Addition to the Russell Microcap® Index
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics to Participate in Upcoming Cowen 43rd Annual Health Care Conference
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From GlycoMimetics, Inc.
    Via Business Wire
    Tickers GLYC
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.